One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress

Blood

Volumn 123, Issue 22, 2014, Pages 3440-3451

  Zhou, Ping ^a   Ma, Xun ^a   Iyer, Lakshmanan ^b   Chaulagain, Chakra ^a   Comenzo, Raymond L ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; BH3 PROTEIN; CASPASE 3; CASPASE 7; EFFECTOR CASPASE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PROTEIN NOXA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL VIABILITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE POOL; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOGLOBULIN PRODUCTION; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; SECRETION (PROCESS); UNFOLDED PROTEIN RESPONSE; UPREGULATION;

AMYLOIDOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULINS; NEOPLASMS, PLASMA CELL; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; UNFOLDED PROTEIN RESPONSE;

EID: 84901722217     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-535187     Document Type: Article

References (50)

1. Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ. Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nat Clin Pract Cardiovasc Med. 2009;6(2):128-133.
2. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-5130.
3. Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013; 88(5):416-425.
4. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematol Am Soc Hematol Educ Program. 2010;2010(1):287-294.
5. Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (Al). Subcell Biochem. 2012;65:609-642.
6. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4(4):321-329. (Pubitemid 36432313)
7. Feige MJ, Groscurth S, Marcinowski M, et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell. 2009;34(5): 569-579.
8. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis. 2006;11(1):5-13. (Pubitemid 43151639)
9. Ryno LM, Wiseman RL, Kelly JW. Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr Opin Chem Biol. 2013;17(3): 346-352.
10. Arendt BK, Ramirez-Alvarado M, Sikkink LA, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008;112(5):1931-1941.
11. Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2012;12(1):49-58.
12. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714-720.
13. Brito JL, Davies FE, Gonzalez D, Morgan GJ. Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J Immunol Methods. 2008; 333(1-2):147-155.
14. Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005;128(5):636-644. (Pubitemid 40343233)
15. Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood. 2008; 111(2):549-557.
16. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24(13):1547-1548. (Pubitemid 351911712)
17. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):Article3.
18. Saeed AI, Bhagabati NK, Braisted JC, et al. TM4 microarray software suite. Methods Enzymol. 2006;411:134-193.
19. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
20. Feng G, Shaw P, Rosen ST, Lin SM, Kibbe WA. Using the bioconductor GeneAnswers package to interpret gene lists. Methods Mol Biol. 2012;802: 101-112.
21. Hamilton MS, Ball J, Bromidge E, Lowe J, Franklin IM. Characterization of new IgG lambda myeloma plasma cell line (EJM): a further tool in the investigation of the biology of multiple myeloma. Br J Haematol. 1990;75(3):378-384. (Pubitemid 20233283)
22. Cao SS, Kaufman RJ. Unfolded protein response. Curr Biol. 2012;22(16):R622-R626.
23. Fribley A, Zhang K, Kaufman RJ. Regulation of apoptosis by the unfolded protein response. Methods Mol Biol. 2009;559:191-204.
24. Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67(11): 5418-5424. (Pubitemid 46997282)
25. Morales AA, Kurtoglu M, Matulis SM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1- expressing myeloma cells. Blood. 2011;118(5): 1329-1339.
26. Lin FR, Huang SY, Hung KH, et al. ASK1 promotes apoptosis of normal and malignant plasma cells. Blood. 2012;120(5):1039-1047.
27. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184-190.
28. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12): 4907-4916. (Pubitemid 43882644)
29. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2): 89-102.
30. Davenport EL, Morgan GJ, Davies FE. Untangling the unfolded protein response. Cell Cycle. 2008; 7(7):865-869. (Pubitemid 351573778)
31. Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma. 2009;50(6): 974-984.
32. White-Gilbertson S, Hua Y, Liu B. The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front Genet. 2013;4:109.
33. Haas IG, Wabl MR. Immunoglobulin heavy chain toxicity in plasma cells is neutralized by fusion to pre-B cells. Proc Natl Acad Sci USA. 1984;81(22): 7185-7188. (Pubitemid 15216721)
34. Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J Biol Chem. 1997;272(7):4327-4334. (Pubitemid 27078506)
35. Hebert DN, Gierasch LM. The molecular dating game: an antibody heavy chain hangs loose with a chaperone while waiting for its life partner. Mol Cell. 2009;34(6):635-636.
36. Corcos D, Osborn MJ, Matheson LS, et al. Immunoglobulin aggregation leading to Russell body formation is prevented by the antibody light chain. Blood. 2010;115(2):282-288.
37. Zou X, Piper TA, Smith JA, Allen ND, Xian J, Brüggemann M. Block in development at the pre-B-II to immature B cell stage in mice without Ig kappa and Ig lambda light chain. J Immunol. 2003;170(3):1354-1361. (Pubitemid 36139502)
38. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9): 1437-1444. (Pubitemid 34925779)
39. Magrangeas F, Cormier ML, Descamps G, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004; 103(10):3869-3875. (Pubitemid 38596307)
40. Kühnemund A, Liebisch P, Bauchmüller K, et al. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135(3):477-484.
41. Qu X, Zhang L, Fu W, et al. An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers. Leuk Lymphoma. 2010;51(10): 1844-1849.
42. Wang Q, Mora-Jensen H, Weniger MA, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA. 2009;106(7):2200-2205.
43. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene. 2008;27(6): 741-754. (Pubitemid 351186310)
44. Mannava S, Zhuang D, Nair JR, et al. KLF9 is a novel transcriptional regulator of bortezomiband LBH589-induced apoptosis in multiple myeloma cells. Blood. 2012;119(6):1450-1458.
45. Rizzatti EG, Mora-Jensen H, Weniger MA, et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma. 2008;49(4):798-808. (Pubitemid 351517227)
46. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819-829.
47. Phipps JE, Kestler DP, Foster JS, et al. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol. 2010;38(11):1006-1013.
48. Hovey BM, Ward JE, Soo Hoo P, O'Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 2011;18(12):1150-1156.
49. Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA. 2010;107(17): 7904-7909.
50. Zhou J, Tiemann K, Chomchan P, et al. Dual functional BAFF receptor aptamers inhibit ligandinduced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res. 2013;41(7):4266-4283.